Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Nov;33(11):2012–2015. doi: 10.1128/aac.33.11.2012

Teicoplanin pharmacokinetics in patients undergoing continuous ambulatory peritoneal dialysis after intravenous and intraperitoneal dosing.

D R Guay 1, W M Awni 1, C E Halstenson 1, M T Kenny 1, W F Keane 1, G R Matzke 1
PMCID: PMC172806  PMID: 2532874

Abstract

The pharmacokinetics of teicoplanin after single 6-mg/kg intravenous and intraperitoneal doses were studied in five noninfected patients undergoing continuous ambulatory peritoneal dialysis. Biological samples were assayed for teicoplanin content by a microbiological assay technique. Terminal disposition half-life (266.4 +/- 51.9 h [mean +/- standard error of the mean]) was prolonged and total body clearance (0.040 +/- 0.004 ml/min per kg) was reduced compared with values previously reported in subjects with normal renal function. The volume of distribution at steady state (1.15 +/- 0.19 liters/kg) was higher than values previously reported in subjects with normal renal function (0.56 to 0.72 liter/kg). Peritoneal dialysis clearance (0.007 +/- 0.001 ml/min per kg) accounted for only 16.1% of total body clearance. The absolute systemic bioavailability of teicoplanin after intraperitoneal administration was 81.5 +/- 10.7%.

Full text

PDF
2012

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonati M., Traina G. L., Villa G., Salvadeo A., Gentile M. G., Fellin G., Rosina R., Cavenaghi L., Buniva G. Teicoplanin pharmacokinetics in patients with chronic renal failure. Clin Pharmacokinet. 1987 Apr;12(4):292–301. doi: 10.2165/00003088-198712040-00003. [DOI] [PubMed] [Google Scholar]
  2. Bowley J. A., Pickering S. J., Scantlebury A. J., Ackrill P., Jones D. M. Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):133–139. doi: 10.1093/jac/21.suppl_a.133. [DOI] [PubMed] [Google Scholar]
  3. Brouard R. J., Kapusnik J. E., Gambertoglio J. G., Schoenfeld P. Y., Sachdeva M., Freel K., Tozer T. N. Teicoplanin pharmacokinetics and bioavailability during peritoneal dialysis. Clin Pharmacol Ther. 1989 Jun;45(6):674–681. doi: 10.1038/clpt.1989.89. [DOI] [PubMed] [Google Scholar]
  4. Carver P. L., Nightingale C. H., Quintiliani R., Sweeney K., Stevens R. C., Maderazo E. Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers. Antimicrob Agents Chemother. 1989 Jan;33(1):82–86. doi: 10.1128/aac.33.1.82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Del Favero A., Menichetti F., Bucaneve G., Minotti V., Pauluzzi S. Septicaemia due to gram-positive cocci in cancer patients. J Antimicrob Chemother. 1988 Apr;21 (Suppl 100):157–165. doi: 10.1093/jac/21.suppl_c.157. [DOI] [PubMed] [Google Scholar]
  6. Domart Y., Pierre C., Clair B., Garaud J. J., Regnier B., Gibert C. Pharmacokinetics of teicoplanin in critically ill patients with various degrees of renal impairment. Antimicrob Agents Chemother. 1987 Oct;31(10):1600–1604. doi: 10.1128/aac.31.10.1600. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Falcoz C., Ferry N., Pozet N., Cuisinaud G., Zech P. Y., Sassard J. Pharmacokinetics of teicoplanin in renal failure. Antimicrob Agents Chemother. 1987 Aug;31(8):1255–1262. doi: 10.1128/aac.31.8.1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Greenwood D. Microbiological properties of teicoplanin. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):1–13. doi: 10.1093/jac/21.suppl_a.1. [DOI] [PubMed] [Google Scholar]
  9. Guay D., Klicker R., Pence T., Peterson P. In vitro antistaphylococcal activity of teicoplanin and ciprofloxacin in peritoneal dialysis effluent. Eur J Clin Microbiol. 1986 Dec;5(6):661–663. doi: 10.1007/BF02013294. [DOI] [PubMed] [Google Scholar]
  10. Harding I., Garaud J. J. Teicoplanin in the treatment of infections caused by coagulase-negative staphylococci. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):93–103. doi: 10.1093/jac/21.suppl_a.93. [DOI] [PubMed] [Google Scholar]
  11. Lagast H., Dodion P., Klastersky J. Comparison of pharmacokinetics and bactericidal activity of teicoplanin and vancomycin. J Antimicrob Chemother. 1986 Oct;18(4):513–520. doi: 10.1093/jac/18.4.513. [DOI] [PubMed] [Google Scholar]
  12. Matzke G. R., Zhanel G. G., Guay D. R. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986 Jul-Aug;11(4):257–282. doi: 10.2165/00003088-198611040-00001. [DOI] [PubMed] [Google Scholar]
  13. Micozzi A., Venditti M., Brandimarte C., Baiocchi P., Martino P., Serra P. Efficacy of teicoplanin as antimicrobial treatment of severe nosocomial infections caused by gram-positive bacteria: a preliminary study. Chemioterapia. 1988 Apr;7(2):101–104. [PubMed] [Google Scholar]
  14. Neville L. O., Baillod R. A., Brumfitt W., Hamilton-Miller J. M. Efficacy and safety of teicoplanin in gram-positive peritonitis in patients on peritoneal dialysis. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):123–131. doi: 10.1093/jac/21.suppl_a.123. [DOI] [PubMed] [Google Scholar]
  15. Neville L. O., Baillod R., Grady D., Brumfitt W., Hamilton-Miller J. M. Teicoplanin in patients with chronic renal failure on dialysis: microbiological and pharmacokinetic aspects. Int J Clin Pharmacol Res. 1987;7(6):485–490. [PubMed] [Google Scholar]
  16. Paton T. W., Cornish W. R., Manuel M. A., Hardy B. G. Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1985 Sep-Oct;10(5):404–425. doi: 10.2165/00003088-198510050-00003. [DOI] [PubMed] [Google Scholar]
  17. Pryka R. D., Rodvold K. A., Rotschafer J. C. Teicoplanin: an investigational glycopeptide antibiotic. Clin Pharm. 1988 Sep;7(9):647–658. [PubMed] [Google Scholar]
  18. Ripa S., Ferrante L., Mignini F., Falcioni E. Pharmacokinetics of teicoplanin. Chemotherapy. 1988;34(3):178–184. doi: 10.1159/000238568. [DOI] [PubMed] [Google Scholar]
  19. Rosina R., Villa G., Danese A., Cavenaghi L., Picardi L., Salvadeo A. Pharmacokinetics of teicoplanin in the elderly. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):39–45. doi: 10.1093/jac/21.suppl_a.39. [DOI] [PubMed] [Google Scholar]
  20. Rotschafer J. C., Garrison M. W., Rodvold K. A. Therapeutic update on glycopeptide and lipopeptide antibiotics. Pharmacotherapy. 1988;8(4):211–219. doi: 10.1002/j.1875-9114.1988.tb04076.x. [DOI] [PubMed] [Google Scholar]
  21. Somma S., Gastaldo L., Corti A. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob Agents Chemother. 1984 Dec;26(6):917–923. doi: 10.1128/aac.26.6.917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Tarral E., Jehl F., Tarral A., Simeoni U., Monteil H., Willard D., Geisert J. Pharmacokinetics of teicoplanin in children. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):47–51. doi: 10.1093/jac/21.suppl_a.47. [DOI] [PubMed] [Google Scholar]
  23. Terragna A., Ferrea G., Loy A., Danese A., Bernareggi A., Cavenaghi L., Rosina R. Pharmacokinetics of teicoplanin in pediatric patients. Antimicrob Agents Chemother. 1988 Aug;32(8):1223–1226. doi: 10.1128/aac.32.8.1223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Traina G. L., Bonati M. Pharmacokinetics of teicoplanin in man after intravenous administration. J Pharmacokinet Biopharm. 1984 Apr;12(2):119–128. doi: 10.1007/BF01059273. [DOI] [PubMed] [Google Scholar]
  25. Traina G. L., Gentile M. G., Fellin G., Rosina R., Cavenaghi L., Buniva G., Bonati M. Pharmacokinetics of teicoplanin in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol. 1986;31(4):501–504. doi: 10.1007/BF00613532. [DOI] [PubMed] [Google Scholar]
  26. Tsukayama D. T., Guay D. R., Gustilo R. B., Wicklund B., Gruninger R., Peterson P. K. The effect of anaerobiosis on antistaphylococcal antibiotics. Orthopedics. 1988 Sep;11(9):1285–1289. doi: 10.3928/0147-7447-19880901-10. [DOI] [PubMed] [Google Scholar]
  27. Van Laethem Y., Hermans P., De Wit S., Goosens H., Clumeck N. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J Antimicrob Chemother. 1988 Jan;21 (Suppl A):81–87. doi: 10.1093/jac/21.suppl_a.81. [DOI] [PubMed] [Google Scholar]
  28. Verbist L., Tjandramaga B., Hendrickx B., Van Hecken A., Van Melle P., Verbesselt R., Verhaegen J., De Schepper P. J. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob Agents Chemother. 1984 Dec;26(6):881–886. doi: 10.1128/aac.26.6.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Walsh B., Drabu Y. J., Mehtar S., Blakemore P. H. Open study of teicoplanin in gram-positive infections. Int J Clin Pharmacol Res. 1988;8(2):99–100. [PubMed] [Google Scholar]
  30. Webster A., Wilson A. P., Williams A. H., Treasure T., Grüneberg R. N. The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis. Postgrad Med J. 1987 Aug;63(742):621–624. doi: 10.1136/pgmj.63.742.621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Wise R., Donovan I. A., McNulty C. A., Waldron R., Andrews J. M. Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration. J Hosp Infect. 1986 Mar;7 (Suppl A):47–55. doi: 10.1016/0195-6701(86)90007-1. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES